Drugmaker Shire said Friday it is recalling one batch of its Gaucher disease treatment Vpriv because particulate matter was discovered in some vials of the drug.
Shire said small amounts of particulate matter were found in three lots of the drug. All three of those lots came from one batch. The company said the particulate matter is stainless steel and barium sulfate. Shire said it believes the safety risk to patients is low and no complaints or side effects have been reported, but serious side effects can be associated with particulate that contains barium sulfate.
The Dublin-based company said the recalled batch should not be used.
Gaucher disease is a rare genetic disorder that can cause liver and neurological problems. The condition is caused by an enzyme deficiency, and Vpriv is designed to replace the deficient or missing enzyme. Shire says revenue from Vpriv grew 12 percent to $342.7 million in 2013. The company had $4.93 billion in total revenue.
U.S. shares of Shire PLC lost 23 cents to $154.61 in afternoon trading.